EDGAR Filing Documents for 0001193125-23-163082

Form 8-K - Current report:

SEC Accession No. 0001193125-23-163082

Filing Date

2023-06-08

Accepted

2023-06-08 09:13:29

Documents

Period of Report

2023-06-06

Items

Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d516868d8k.htm iXBRL	8-K	40684
2	EX-3.1	d516868dex31.htm	EX-3.1	6651
3	EX-3.2	d516868dex32.htm	EX-3.2	127816
	Complete submission text file	0001193125-23-163082.txt		337795

Data Files

Seq	Description	Document	Type	Size
4	XBRL TAXONOMY EXTENSION SCHEMA	stsa-20230606.xsd	EX-101.SCH	2855
5	XBRL TAXONOMY EXTENSION LABEL LINKBASE	stsa-20230606_lab.xml	EX-101.LAB	19481
6	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	stsa-20230606_pre.xml	EX-101.PRE	12156
8	EXTRACTED XBRL INSTANCE DOCUMENT	d516868d8k_htm.xml	XML	3655

Mailing Address 4819 EMPEROR BOULEVARD SUITE 340 DURHAM NC 27703

Business Address 4819 EMPEROR BOULEVARD SUITE 340 DURHAM NC 27703 415-505-0809

Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)